BridgeBio Oncology Therapeutics is trading at $2.61, down -8.42% in pre-market, with biotech-sector weakness the likeliest explanation. - Biotech ETF XBI was down 3.65% pre-market; supplied broad-index moves were smaller and mixed. - No clear company-specific catalyst was identified for October 20. The latest located release was an October 12 inducement-grant announcement; its clinical-data update was dated September 8, so neither appears to be new overnight news. - Volume data was unavailable.